title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Dose reduction, suspension, or discontinuation of chemotherapy due to CIPN | CIPN | The incidences of chemotherapy dose reduction, suspension, and discontinuation due to all causes were 7.7%, 23.1%, and 34.6%, and those due to CIPN were 5.8%, 1.9%, and 3.8%, respectively (Table Incidence of dose reduction, suspension, or discontinuation of chemotherapy
| PMC10640752 | |
Changes in CIPN severity | CIPN | CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, ADVERSE EVENT | At baseline, 92.3% (48/52) of patients had grade 2 CIPN (Fig. Numbers of patients with change in grade of chemotherapy-induced peripheral neuropathy according to the Common Terminology Criteria for Adverse Events over 12 weeks (full analysis set). Data are presented as percentage of patients. Changes in FACT/GOG-NTX an... | PMC10640752 |
Changes in EQ-5D-5L index value and PGIC score | The change in EQ-5D-5L index value from baseline to week 12 was 0.0128 (95% CI, − 0.0406 to 0.0663) ( | PMC10640752 | ||
Safety | treatment-emergent adverse events, chemotherapy-induced peripheral neuropathy, adverse drug reactions | CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, ADVERSE DRUG REACTIONS | The incidence of treatment-emergent adverse events (TEAEs) was 76.9% (40/52 patients), and the incidence of AEs related to the study drug (ADRs) was 30.8% (16/52 patients) (Table Incidences of adverse drug reactions in patients with chemotherapy-induced peripheral neuropathy in the MiroCIP interventional study (safety ... | PMC10640752 |
Discussion | CIPN | CIPN includes both painful and non-painful symptoms, both of which can lead to dose reduction or discontinuation of chemotherapy [ | PMC10640752 | |
Pain and tingling | neuropathic pain, Pain, cancer, CIPN, pain, Tingling, NRS | DIABETIC PERIPHERAL NEUROPATHY, TINGLING, CANCER | In the present study, NRS score decreased by − 1.5 (27.3%) by week 4 and remained stable at the end of the treatment period (− 1.7, 30.9% reduction at week 12 LOCF). Patients with a baseline NRS of ≥ 6 experienced a − 2.9 reduction (38.7%) in NRS score. Our results are similar to the effects of duloxetine observed in a... | PMC10640752 |
Completion of chemotherapy | CIPN | CIPN is often the main reason for dose modulation or discontinuation of chemotherapy, both of which can negatively affect patient outcomes [ | PMC10640752 | |
CIPN severity | peripheral neuropathy, CIPN, pain | MOTOR NEUROPATHY, PERIPHERAL NEUROPATHY | Use of symptomatic pain relief medications during chemotherapy may contribute to worsening of CIPN severity, because suppression of subjective symptoms may interfere with appropriate decisions on when to reduce or discontinue chemotherapy. To assess this risk in the present study, the severity of peripheral neuropathy ... | PMC10640752 |
Safety | dizziness, cancer, somnolence | CANCER, EDEMA PERIPHERAL | Our results indicate that mirogabalin is well tolerated in patients with cancer during chemotherapy. Most ADRs in the present study were mild or moderate, and predominantly somnolence, oedema peripheral, and dizziness. These ADRs are similar to those reported for previous studies of mirogabalin and pregabalin [ | PMC10640752 |
Limitations | CIPN, multiple cancer, pain | MULTIPLE CANCER | There are some limitations in the present study. First, the study was an open-label, single-arm study without a comparator group; a placebo group could not be used due to ethical concerns. Therefore, the results cannot be definitively attributed to mirogabalin. However, the degree of pain improvement was similar to tha... | PMC10640752 |
Conclusions | CIPN, neurotoxic, pain | The MiroCIP interventional study shows that mirogabalin has an acceptable safety profile and is effective for pain and tingling due to CIPN in patients with colorectal, gastric, non-small-cell lung, and breast cancers who receives oxaliplatin- and taxane-based chemotherapy. The findings of this study suggest that mirog... | PMC10640752 | |
Acknowledgements | The authors wish to thank the participants of this study and all the institutions and investigators who participated (listed in Supplementary Table Consortium NameOther investigators than authors in the MiroCIP study Group as follows: Go Saito
| PMC10640752 | ||
Authors’ contributions | TD | SM, TD, TSuzuki, YN, TK, MT, TSuichi, and SKuwabara contributed to the conception or design of this study, and to the acquisition, analysis, and interpretation of data; they also drafted this manuscript. SKodama and KS contributed to the conception or design of the study. Finally, all named authors have made substantia... | PMC10640752 | |
Funding | This study was supported by Daiichi Sankyo Co., Ltd., Tokyo, Japan, which also provided funding for medical writing support. Daiichi Sankyo Co., Ltd. was involved in the study design, planning of the data analysis, data interpretation, and development of the manuscript, but was not in data management or statistical ana... | PMC10640752 | ||
Availability of data and materials | The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author and Daiichi Sankyo Co., Ltd., a study sponsor, on reasonable request. | PMC10640752 | ||
Declarations | PMC10640752 | |||
Ethics approval and consent to participate | CRB | The MiroCIP study was preapproved by the Chiba University Certified Clinical Research Review Board (CRB no. CRB3180015), which notified all participating centers of the approval.The study was carried out in accordance with the Clinical Research Act in Japan; the CRB conducted a central review, and after the study had b... | PMC10640752 | |
Consent for publication | Not applicable. | PMC10640752 | ||
Competing interests | TD | SM, TD, TSuzuki, YN, TK, MT, TSuichi, and SKuwabara received lecture fees from Daiichi Sankyo Co., Ltd. SKodama and KS are employees of Daiichi Sankyo Co., Ltd. | PMC10640752 | |
References | PMC10640752 | |||
Subject terms | PLASMA CELL DYSCRASIAS, MULTIPLE MYELOMA (MM), DISEASE, EVENTS, MINIMAL RESIDUAL DISEASE (MRD) | Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseline (480 patients) and at the ... | PMC9812999 | |
Introduction | MULTIPLE MYELOMA (MM), MYELOMA | Novel therapeutics have significantly improved response rates as well as the depth of response in patients with multiple myeloma (MM) [The minimally invasive technology mass spectrometry (MS), which is amenable to automation, is emerging as a promising approach for detecting and monitoring monoclonal proteins in the pe... | PMC9812999 | |
Patients and methods | PMC9812999 | |||
Study design and participants | newly-diagnosed MM, peripheral blood | For quantitative immunoprecipitation mass spectrometry (QIP-MS), we included peripheral blood (PB) serum samples from 480 GMMG-MM5 patients at baseline, from 444 of these patients after three cycles of either VCD or PAd induction therapy and prior to HDM/ASCT, from 305 patients prior to maintenance treatment or observa... | PMC9812999 | |
Mass spectrometry for detection of monoclonal immunoglobulins | QIP-MS was carried out using the automated EXENT | PMC9812999 | ||
Risk stratification by fluorescence in situ hybridization and the revised International Staging System | Interphase fluorescence in situ hybridization (FISH) analysis was performed as described previously [ | PMC9812999 | ||
Allele-specific oligonucleotide polymerase chain reaction for detection of minimal residual disease | SEPARATION | For MRD analyses, DNA was extracted after density gradient separation of lymphocytes from bone marrow (BM) aspirates, which was then stored at −20 °C until analysis. We used patient-specific quantitative allele-specific oligonucleotide PCR (qASO-PCR) assays on immunoglobulin heavy chain (IgH) and kappa/lambda (k/λ) lig... | PMC9812999 | |
Statistical design and analysis | death | REGRESSION, EVENT | The Kaplan-Meier method was used for survival analyses. PFS time was measured from the respective landmark to relapse or death from any cause, whichever occurred first. OS was defined as time from the respective landmark until death from any cause. For analyses of sustained MS from start of maintenance/observation unti... | PMC9812999 |
Results | PMC9812999 | |||
Mass spectrometry results are associated with outcome at multiple time points | tumor | TUMOR | We used the QIP-MS for longitudinal monitoring of 480 patients with PB serum samples at baseline and at least one additional time point. Combining MS for intact immunoglobulins and free light chains, a monoclonal immunoglobulin could be identified at baseline for each patient, which allowed us to longitudinally track t... | PMC9812999 |
Prognostic value of mass spectrometry at defined time points. | DISEASE | Progression-free (PFS) and overall survival (OS) of GMMG-MM5 patients stratified by the mass spectrometry test result (negative/positive) after induction therapy (A recent study demonstrated that the extended half-life of IgG could impact disease monitoring by MS [ | PMC9812999 | |
The mass spectrometry test result constitutes an independent prognostic factor | Next, we evaluated the prognostic value of MS testing at the three defined time points in a multivariable model, which included age at diagnosis, gender, treatment arm, R-ISS stages and gain(1q21) status (Fig. | PMC9812999 | ||
Independent prognostic impact of mass spectrometry and its combination with established high-risk markers. | Results of a multivariable model for PFS from the start of maintenance therapy/observation ( | PMC9812999 | ||
Mass spectrometry improves the prognostic value of established risk markers | DISEASE | The prognostic value of the depth of response, as assessed by conventional response, MRD in the BM or functional imaging, is impacted by baseline disease features, such as high-risk cytogenetics [ | PMC9812999 | |
Mass spectrometry in patients with complete response and the impact of lenalidomide maintenance | We recently showed that omitting maintenance in CR patients resulted in significantly worse outcomes [ | PMC9812999 | ||
Sequential testing improves the prognostic value of mass spectrometry | Long-term deep responses have been associated with improved survival in MM [ | PMC9812999 | ||
Mass spectrometry complements bone marrow minimal residual disease assessment | The position of MS regarding detection of MRD in the BM is one important question. MRD data were not systematically collected within the GMMG-MM5 trial. However, for 45 patients BM MRD (sensitivity 1 × 10 | PMC9812999 | ||
Discussion | tumor, MM | RESIDUAL DISEASE, TUMOR | MS has been proposed as a minimally invasive complementary approach for monitoring of residual disease in MM patients [In both the STAMINA [From a clinical point of view, it is an important question if QIP-MS results can be used to guide treatment decisions. While we show a significant impact of single MS testing on PF... | PMC9812999 |
Supplementary information | The online version contains supplementary material available at 10.1038/s41408-022-00772-9. | PMC9812999 | ||
Acknowledgements | MYELOMA | This project was supported by the Dietmar-Hopp Foundation. The GMMG-MM5 trial was supported by grants from Celgene, Janssen-Cilag, Chugai and The Binding Site. The GMMG thanks the Koordinierungszentrum für Klinische Studien (KKS) Heidelberg for the support of the trial and data monitoring. The GMMG also thanks all inve... | PMC9812999 | |
Author contributions | Conception and design: E.K.M., N.W. Provision of study material or patients: E.K.M., C.S., K.C.W., M.M., I.W.B., M.H., H.J.S., M.S.R., H.G. Coordinated processing of peripheral blood and bone marrow samples: D.H., A.S. Administrative support: U.B., H.G. FISH analyses: A.J. Mass spectrometry: O.B. Data analysis and inte... | PMC9812999 | ||
Funding | The GMMG initiated and designed the GMMG-MM5 trial and the retrospective MS study. Celgene, Janssen-Cilag, Chugai, and The Binding Site funded the trial and investigational medicinal products (bortezomib, lenalidomide). The Binding Site performed and funded the MS testing. The Dietmar Hopp Foundation in part funded inf... | PMC9812999 | ||
Data availability | Data from the GMMG-MM5 trial and QIP-MS samples is not publicly available. For requests, please contact the corresponding author. | PMC9812999 | ||
Conflict of interest | E.K.M.: Consulting or Advisory Role, Honoraria, Research Funding, and Travel Accommodations and Expenses—Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline and Takeda. Oscar Berlanga is an employee of The Binding Site Group Ltd., UK. M.H.: Consulting or Advisory Role, Honoraria: Amgen, Bayer... | PMC9812999 | ||
References | PMC9812999 | |||
1. Introduction | habitual behaviors, habitual behaviors like substance, addictive behaviors, adverse health behavior measure, substance abuse | REGRESSION, SECONDARY | Vocational students are a risk group for problematic substance use and addictive behaviors. The study aim was to evaluate the effects of an app-based intervention on tobacco, e-cigarettes, alcohol, and cannabis use as well as gambling and digital media-related behaviors in the vocational school setting. A total of 277 ... | PMC9915308 |
2. Materials and Methods | PMC9915308 | |||
2.1. Study Design | We conducted a two-arm multicenter, cluster-randomized, wait-list controlled trial with repeated measurements. Data were collected class-wise in schools at baseline and follow-up by using digital questionnaires and throughout the app-based intervention (only IG, CG did not use the app). The detailed study protocol is a... | PMC9915308 | ||
2.2. Participants, Recruitment, and Randomization | RECRUITMENT, RECRUITMENT, STILL | Schools were consecutively recruited via local authorities or direct contact using digital and printed information materials, school conferences, etc. After initial agreement from school principalities, research staff, social school workers, or principals contacted the teachers at the participating school and informed ... | PMC9915308 | |
2.3. Intervention and Setting | “Meine Zeit ohne—Die Challenge“ (“My time off—the Challenge”) is an app-based intervention developed for implementation in vocational schools. It is based on the ideas of a project called “initiated abstinence” [ | PMC9915308 | ||
2.4. Data Collection and Outcomes | Participation in the survey and intervention (IG) was voluntary, so the number of participating students could differ noticeably from previously announced class sizes. There were no exclusion criteria. After interested teachers were identified at a respective school, assessment/introduction dates were set for each clas... | PMC9915308 | ||
2.5. Measurements | substance-related behavior | Sociodemographic data included age, gender, income, parent’s migration history (yes/no), income, highest previous education, educational area, and educational progress. Primary outcomes were substance-related behavior in the last 30 days using binary answers (yes/no) as well as quantitative instruments. The assessment ... | PMC9915308 | |
2.6. Statistical Analysis | REGRESSION, REGRESSIONS | Based on previous studies [For descriptive baseline data, we used standard code to tabulate ratios for data on nominal and ordinal scale levels. Metric data are presented with means and standard deviations (SD). As part of the attrition analysis, linear regressions were applied to evaluate differences between students ... | PMC9915308 | |
4. Discussion | multiple behaviors, unhealthy behaviors | Our study shows first indications of a positive effect of the app-based intervention in terms of an overall improvement of health-related behavior among vocational students.With that, the study assessed behavior changes that exceeded the 2-week period of the challenge. It should be stressed that students were not encou... | PMC9915308 | |
Limitations | REGRESSION, ASSOCIATED CONDITIONS, RECRUITMENT | This study has a number of limitations. First, randomization on class level reduced the overall clusters to 277. Despite efforts like pairing randomization units by similar characteristics, differences between the IG and CG participants were found, leading to possible selection bias. This has been taken into account by... | PMC9915308 | |
5. Conclusions | SECONDARY | Substance use and digital media exposure are major health risks for adolescents and young adults beyond secondary school. At the same time, they form habits over time, which are already present at young adulthood. This is the first time that a prevention program for vocational schools was rigorously evaluated in a rand... | PMC9915308 | |
Author Contributions | M.M., R.H., N.A., R.T., K.L. and L.K. conceived the study, initiated the study design and obtained funding; B.P., M.R. and K.G. were responsible for data curation, B.P. and M.M. for the data analysis. M.M., N.A., K.L., L.K., M.R., E.G.d.M. and B.P. developed the methodology for the intervention app and all study materi... | PMC9915308 | ||
Institutional Review Board Statement | Approval for the study was obtained from the ethics committee of the Center for Psychosocial Medicine at the University Medical Center Hamburg Eppendorf and the responsible school authorities at each study site (Center for Education Monitoring and Quality Development at schools in Hamburg, IfBQ; the Center for Preventi... | PMC9915308 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC9915308 | ||
Data Availability Statement | The study material (information sheets) is available to the public and can be found on the following website | PMC9915308 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC9915308 | ||
References | ’ behavior | Participants flow chart.Change in IG participants’ behavior compared to the control group (odds ratios adjusted for highest education with 95% CI).Baseline statistics, attrition analysis, and differences between the intervention and control groups.Assessed behavioral and well-being variables, criteria on which a health... | PMC9915308 | |
1. Introduction | colorectal cancer, tumor, Tumor, CRC, malignant cancer, cancer, TCGA, deaths, Cancer | COLORECTAL CANCER, INFILTRATION, TUMOR, TUMOR, CANCER, CANCER | It’s well known that N6-methyladenosine (m6A) modification is the most abundant modification in multiple RNA species. miRNAs play important roles in m6A modification and are closely related with occurrence and development of colorectal cancer (CRC). Thus, the aim of this study was to identify the prognostic value of m6... | PMC10659607 |
2. Materials and Methods | PMC10659607 | |||
2.1. Data collection | CRC | The date of miRNA sequencing, mRNA sequencing (FPKM value), mutation expression, and corresponding clinical information of CRC were acquired from TCGA. The mRNA sequencing was transformed into log2(TPM+1). A total of 25 m6A modification regulators were selected from previous research including 8 writers (METTL3, METTL1... | PMC10659607 | |
2.2. Identification of m6A-related miRNAs | tumor | TUMOR | The workflow was showed in Figure Workflow of the whole study. DEMs = differentially expressed miRNAs, TMB = tumor mutation burden. | PMC10659607 |
2.3. Construction of risk score | CRC | REGRESSION | In order to select the survival-related miRNAs, univariate Cox regression analysis was applied on m6A-related miRNAs, and the acquired miRNAs were adopted into the next analysis. To explore the mechanisms of the miRNAs in CRC, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was used via the website t... | PMC10659607 |
2.4. TMB and tumor immune microenvironment | CRC | INFILTRATION | TMB is defined as the total number of mutations per million bases and was reported to be related with immune checkpoint inhibitors.To explore the correlation between degree of immune cell infiltration and risk score, ESTIMATE algorithm was performed to calculate Immune score, Stromal score and Estimate score using “est... | PMC10659607 |
2.5. Drug sensitivity of risk score | Considering the potential of risk score to predict drug sensitivity, the half-maximal inhibitory concentration (IC50) of the selected drugs was compared between high-risk group and low-risk group via “pRRophetic” package. | PMC10659607 | ||
2.6. Total RNA extraction and quantitative real-time PCR | PRIMARY TUMOR, METASTASIS, METASTATIC TUMOR | To explore the roles of the miRNAs in CRC metastasis, the expression of the miRNAs was compared between SW480 and SW620 cells, which were isolated from primary tumor and metastatic tumor in abdomen of single CRC patient, respectively. Total RNA was isolated from the cell lines using Total RNA Extractor (No. B511311; Sa... | PMC10659607 | |
2.7. Statistical analysis | All statistical analysis was conducted by R language 4.0.3 ( | PMC10659607 | ||
3. Results | PMC10659607 | |||
3.1. Identification of m6A-related miRNAs | tumor, TCGA, CRC | TUMOR | After differential expression analysis, a total of 526 DEMs were selected (309 upregulated and 217 downregulated) between CRC and normal colorectal tissues in the TCGA dataset (Fig. (A and B) Heatmap and Volcano plot showed the differentially expressed miRNAs between tumor and adjacent normal tissues. (C) The expressio... | PMC10659607 |
3.2. Development and validation of risk score | CRC | REGRESSION, COLORECTAL CANCER, INTERACTION | A total of 29 m6A-related miRNAs were found to be related with survival via univariate Cox regression analysis. These miRNAs may play important roles in m6A modification of CRC, so KEGG pathway analysis was used and the results showed that these miRNAs were enriched in MAPK signaling pathway, Ras signaling pathway, Wnt... | PMC10659607 |
3.3. Establishment of nomogram | CRC | COLORECTAL CANCER | To make risk score more applicable in the clinic, nomogram was established using risk score and clinicopathological parameters, which could provide a better prognostic evaluation for the individual patient. The nomogram contained age, gender, TNM stage and risk score, and risk score was the largest contributors to prog... | PMC10659607 |
3.4. TMB analysis of the risk score | tumor | TUMOR | Immunotherapy has been a promising treatment in CRC, and evidences implied that TMB was closely related to sensibility of immunotherapy. In present study, TMB was significantly higher in the low-risk group ((A) Comparison of TMB levels between high-risk group and low-risk group. (B) The correlation among TMB levels and... | PMC10659607 |
3.5. Correlation of the risk score and tumor immune microenvironment | tumor, TCGA, CRC | TUMOR | The ESTIMATE algorithm was applied to investigate the correlation of the risk score and the immune microenvironment in CRC. Next, Stromal score, Immune score, and ESTIMATE score of all CRC patients were calculated. As is Figure Risk score was associated with tumor immune microenvironment. (A) The boxplot showed the dif... | PMC10659607 |
3.6. Drug sensitivity analysis of the risk score | The “pRRophetic” package was performed to investigate the correction between drug sensitivity and risk score. IC50 of cisplatin was lower in low-risk group compared to high-risk group (The IC50 of cisplatin (A) and gemcitabine (B) in high- and low-risk groups. IC50 = half-maximal inhibitory concentration. | PMC10659607 | ||
3.7. The expression of the miRNAs | PRIMARY TUMOR, METASTASIS, METASTATIC TUMOR | As the 5 miRNAs in risk score were related with the CRC prognosis, we suspected that the miRNAs were related to CRC metastasis. Therefore, the expression of the miRNAs was explored between SW480 and SW620, which were respectively separated from primary tumor and metastatic tumor of CRC. The results showed that miR-328-... | PMC10659607 | |
4. Discussion | cancers, tumor, CRC, head and neck squamous cell carcinomas, TCGA, malignant tumor | CANCERS, METASTASIS, TUMOR, PROLIFERATION, MALIGNANT TUMOR, COLD | It’s known that CRC is a common malignant tumor with high incidence and mortality.In previous studies, miRNAs have been proved to be good prognostic biomarkers in various cancers. The study reported that immune-related miRNA signature could be used to effectively predict the prognosis of head and neck squamous cell car... | PMC10659607 |
5. Conclusion | CRC | INFILTRATION | Present study is the first to investigate the prognostic value of m6A-related miRNAs and constructed a risk score for further application. The risk score was correlated with TMB and immune cells infiltration, which could provide the important information in immunotherapy but also the direction to explore the mechanisms... | PMC10659607 |
Acknowledgments | The authors thank the public availability of the GEO ( | PMC10659607 | ||
Abbreviations: | TCGA, Cancer | COLORECTAL CANCER, CANCER | confidence intervalcolorectal cancerdifferentially expressed miRNAshazard ratiothe half-maximal inhibitory concentrationKyoto Encyclopedia of Genes and Genomesthe least absolute shrinkage and selection operatorN6-methyladenosineThe Cancer Genome Atlastumor mutational burdenXQ and DC contributed equally to this work.The... | PMC10659607 |
References | PMC10659607 | |||
Objectives: | IOL | To compare the subjective and objective visual quality more comprehensively after surgery of the commonly used multifocal intraocular lenses (IOL) and monolocal IOL implants through long-term systematic clinical observation, providing reference and basis for clinical application. | PMC10187746 | |
Methods: | SE, visual disturbance | IOL, NEAR VISION, LENS | Non-randomized controlled trial. A total of 91 (138 eyes) patients between June 2020 and December 2020 were implanted trifocal IOL or monofocal IOL after phacoemulsification in a tertiary class hospital in Wuhan. Monocular testing 3 months after surgery included best-spectacles corrected and uncorrected visual at dista... | PMC10187746 |
Results: | IOL | There was statistically better uncorrected vision acuity with trifocal IOLs in all range, while monofocal IOL had statistically better mesopic contrast sensitivity at specific spatial frequencies and statistically worse defocus curves, spectacles independence, and surgical satisfaction. The trifocal IOL performed bette... | PMC10187746 | |
Conclusion: | cataracts | CATARACTS, IOL | Compared to monofocal IOL, trifocal IOL could provide a full range of clear vision for the majority of patients with simple cataracts, improve the rate of spectacles independence and patient satisfaction. And the objective quality of vision did not show any difference. | PMC10187746 |
Keywords: | IOL, NEAR VISION |
Although patients can have good distance vision after the implantation of monofocal IOL, their vision in intermediate and near remain poor due to the loss of accommodation. Most of the individuals are spectacles independent, but the overall contentment is not high. The new IOL can improve the postoperative distance, i... | PMC10187746 | |
Methods | PMC10187746 | |||
Search method used to find prior related research | LENS | Conduct relevant literature searches on websites such as PubMed, Web of Science, SCI-HUB, with the search keywords including MIOL, contrast sensitivity (CS), and modulation transfer function (MTF); Dysfunctional lens index (DLI), and so on. | PMC10187746 | |
Patient enrollment | age-related cataracts | After approval by the ethics committee, 91 (138 eyes) patients between June 2020 and December 2020, aged >40-years-old, with age-related cataracts, were enrolled consecutively in a non-randomized controlled trial comparing AT LISA tri 839MP (Carl Zeiss Meditec, Jena, Germany) (A group; n=65) and Mi60 (Bausch and Lomb, ... | PMC10187746 | |
Surgical procedure | All the operations were performed by the same doctor. The patients underwent small incision phacoemulsification with an incision at the steep meridian and a central continuous curvilinear capsulorhexis, <5.5 mm in diameter. | PMC10187746 | ||
Intraocular lens selection, IOL power calculations, and targeted refraction | IOL, Barrett universal II formula | IOL, NEAR VISION | A detailed medical history inquiry and explanation of postoperative results were essential before MIOL implantation.Barrett universal II formula was used for all patients. Emmetropia was the targeted refraction for AT LISA tri 839MP, and -0.25D could be used if patients had special requirements for near vision. For Akr... | PMC10187746 |
Subjective visual quality | SE | LENS | Uncorrected vision acuity (UCVA) at a distance (5 m), intermediate (80 cm), and near (40 cm), spherical equivalent (SE), and best-corrected vision acuity (BCVA) at a distance and near were recorded. Also, the best-corrected visual at intermediate was not recorded. We averaged the logarithm of the minimum angle of resol... | PMC10187746 |
Objective visual quality | LENS | Modulation transfer function (MTF) average height, dysfunctional lens index (DLI), and Strehl ratio (SR) were recorded at 3 months after implantation using the iTrace aberrometer (Tracey Technologies Co., Houston, USA). MTF values were measured at spatial frequencies of 5, 10, 15, 20, 25, and 30 cpd at 3-mm pupil diame... | PMC10187746 | |
Statistical analysis | EYE | The SPSS Statistics for Windows, version 26.0 (IBM Corp., Armonk, N.Y., USA) was used for statistical analyses. Confirm all data distribution were normal distribution. For each parameter, the mean values and standard deviations were calculated. Independent sample t-test was used between groups A and B, and statistical ... | PMC10187746 | |
Results | In group A, 2 patients had fundus lesions that were not detected before the operation, and 3 patients in group B were lost to follow-up after the operation. None of these 5 patients were included in the follow-up data analysis. | PMC10187746 | ||
Monocular vision | SE | DISEASE, NEAR VISION | Uncorrected vision acuity at distant - Distance, intermediate, and near vision at 3 months after surgery with LISA tri 839MP and Mi60.n represented the number of eyes followed up after surgery (one case in group A was lost to follow-up, and there were 2 cases of fundus disease in group B not found before the operation.... | PMC10187746 |
Contrast sensitivity function | Across all spatial frequencies, group B scored higher on the monocular, best spectacles corrected contrast sensitivity test except 1.5 cpd without glare than group A at 1 and 3 months (- Contrast sensitivity function and modulation transfer function (MTF) of each group after surgery. CS: contrast sensitivity, cpd: cycl... | PMC10187746 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.